In the context of above-mentioned difficulties, although BRAF and mitogen-activated protein kinase (MEK) inhibitors have proved to contribute remarkably to the survival of CM patients, as per the meta-analysis by Theresa S [30], MEK inhibitors exerted no effect on UM. The gene discussed is BRAF; the disease is cutaneous mastocytosis.